$BSM

Black Stone Minerals (NYSE:BSM) Director D Mark Dewalch Buys 37,650 Shares of Stock

Black Stone Minerals director D Mark Dewalch bought 37,650 shares on May 28 at an average $13.21 each, for about $497,356, according to an SEC filing. After the trade, he owned 431,495 shares. The stock was up 0.3% to open at $13.33. The firm reported May 4 EPS of $0.03 vs $0.22 expected and revenue of $59.36M vs $107.38M.

Original reporting
Published May 29, 2026, 12:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 12:48 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Black Stone Minerals (NYSE:BSM) Director D Mark Dewalch Buys 37,650 Shares of Stock — source image
Decision brief

The 30-second read

$BSMBullishMed
01

Why it matters

For traders, the actionable element is the fresh insider buying disclosure; however, the broader setup is still shaped by the prior quarter’s revenue/earnings miss and the high payout ratio.

02

Market read

A newly disclosed director buy provides mild positive sentiment, but without new guidance it is unlikely to be a standalone driver versus earnings/dividend fundamentals.

03

What to watch

The stock is trading below key moving averages and has a high dividend payout ratio (~94.5%), so sustainability concerns could dominate any sentiment from insider buys.

Relevance 7/10Novelty 6/10Timing: today/this week as the SEC buy is newly disclosed (May 28 transaction; May 29 article)

Background

The piece centers on an SEC-disclosed director share purchase, alongside a recap of the May 4 earnings miss and the May 15 dividend payment.

Company-level read

Ticker impact

$BSMBullishMedium confidence
Context

Director D Mark Dewalch bought 37,650 shares at ~$13.21, increasing his stake by 9.56%, disclosed via SEC filing.

Expected impact

Likely limited near-term impact; may slightly support downside in thin liquidity but not override earnings/dividend fundamentals.

Evidence & confidence

The article provides a concrete Form 4-style buy and position increase, yet no new operational guidance or asset/earnings change beyond the already-reported quarter.

Market effects

Reinforces the narrative that royalty/oil-gas income vehicles can attract insider support, but provides no new sector-wide signal.

None specific beyond US energy/royalty exposure.

Low; company-specific insider transaction with no stated commodity or geopolitical linkage.

Counterpoint

Director buying can be routine diversification/compensation-related and may not signal improved fundamentals after the recent earnings miss.

Key entities

  • D Mark Dewalch

    Director who increased his position by buying 37,650 shares at an average cost of $13.21.

  • Black Stone Minerals, L.P.

    NYSE-listed oil and gas mineral/royalty income vehicle; recently reported a quarter with EPS miss and declared a $0.30 quarterly dividend.

Related articles

$BSMMed

Black Stone Minerals, L.P. (BSM): Results of Operations and Financial Condition

Black Stone Minerals, L.P. (BSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News For Immediate Release Black Stone Minerals, L.P. Reports Second Quarter Results HOUSTON - (BUSINESS WIRE) - Black Stone Minerals, L.P. (NYSE: BSM) ("Black Stone Minerals," "Black Stone," or "the Partnership") today announces its financial and operating results f

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.

$BKRMed

Baker Hughes (BKR) Lands Multi-Year Contract with Pakistan’s OGDC

Baker Hughes (BKR) secured a multi-year contract with Pakistan's OGDC to enhance production from mature oil and gas fields. The deal involves assessing 120 wells and providing tailored redevelopment plans. Baker Hughes aims to use AI and other technologies to improve flow assurance and restore production. The contract aligns with Baker Hughes' strategy to diversify revenue and reduce reliance on short-term drilling cycles, as evidenced by a 49% YoY increase in orders to $10.5 billion in Q2. Howe